Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Double-blind, Placebo Controlled, Randomised Study to Assess the Efficacy and Safety of ZD4054 (Zibotentan) in Combination With Pemetrexed (Alimta®) vs. Pemetrexed Alone in Patients With Non-small Cell Lung Cancer Who Have Failed One Prior Platinum-based Chemotherapy Regimen

NCT00745875 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT00745875
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00745875 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Double-blind, Placebo Controlled, Randomised Study to Assess the Efficacy and Safety of ZD4054 (Zibotentan) in Combination With Pemetrexed (Alimta®) vs. Pemetrexed Alone in Patients With Non-small Cell Lung Cancer Who Have Failed One Prior Platinum-based Chemotherapy Regimen
Lead sponsor
AstraZeneca
Phase
Phase 2
Overall status
Completed
Start date
August 31, 2008
Completion date
January 31, 2010
Enrollment
66 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

lung cancer, non small cell lung cancer